Global Non Animal Alternatives Testing Market Size 2024, Forecast To 2033

11 Mar, 2024

The non-animal alternatives testing market has experienced rapid growth, escalating from $2.08 billion in 2023 to $2.33 billion in 2024, with a compound annual growth rate (CAGR) of 11.9% in the historic period. This growth is attributed to factors such as strong economic growth in emerging markets, high costs of animal studies, increased adoption of in-vitro and in-silico technologies in basic research, rising investments, and a rise in research grants for developing alternative technologies, along with increasing social awareness against animal cruelty. Moving into the future, the market is poised for rapid growth, projecting a size of $3.63 billion in 2028 at a CAGR of 11.8%. The forecasted growth is driven by factors such as government programs for non-animal alternative testing, an increase in the number of research and development activities, and ethical concerns regarding animal experimentations. Key trends in the forecast period include a focus on advancing ooc technology, the use of in silico trials, the development of advanced 3D bio-printed organs and tissues, the use of model organisms, collaborations and partnerships, and rising initiatives and grants to promote animal-free testing.

Global Non Animal Alternatives Testing Market Key Driver

Governmental and non-governmental support significantly fuels the expansion of the non-animal testing market. Regulatory bodies enforce laws promoting non-animal testing methods, while organizations like People for the Ethical Treatment of Animals (PETA) contribute funds for research and development in this area. Initiatives such as PETA India's grant of 7 lakh rupees in 2022 exemplify the commitment to advancing animal-free testing methods. Moreover, countries like Denmark, Brazil, Germany, and others have launched similar research programs, fostering the growth of non-animal testing initiatives. The market size for non-animal testing in 2023 reached A units, projected to expand to B units by 2024 and further to C units by 2028.

Get A Free Sample Of The Global Non Animal Alternatives Testing Market Report

Global Non Animal Alternatives Testing Market Segments

The non-animal alternatives testing market covered in this report is segmented –
1) By Technology: Cell Culture Technology, High Throughput Technology, Molecular Imaging, Omics Technology, Other Technologies
2) By Method: Cellular Assay, Biochemical Assay, In Silico, Ex-Vivo
3) By End-User: Pharmaceutical Industry, Cosmetics And Household Products, Diagnostics, Chemicals Industry, Food And Beverage Industry, Other End Users
By Geography:The regions covered in the non-animal alternatives testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain North America was the largest region in the non-animal alternatives testing in 2023. Western Europe was the second-largest region in the non-animal alternatives testing market report. The regions covered in the non-animal alternatives testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Major Non Animal Alternatives Testing Industry Players

Evotec SE (Cyprotex), Bio-Rad Laboratories, Inc, BioIVT, Emulate, Inc, MatTek Corporation, SGS SA, Gentronix Limited, Promega Corporation, InSphero, VITROCELL Systems GmbH, Abbott India Limited, Becton Dickinson Private Limited, Biocartis Group NV, Bio-Techne India Private Limited, Danaher, Cleaver Scientific, China Tissue Engineering Co., Ltd. (J-TEC), Reprocell, Inc., Organ Technologies Co. Ltd, Mimetas, JRF Global, PharmaCo-Cell Company Ltd, Vessel Inc, Modulus Discovery, Sanofi, F. Hoffmann-La Roche AG, Siemens Healthineers AG, Qiagen N.V, bioMérieux SA, QuantuMDx, Interlabservis, Roche Diagnostics, GeneMe, TestLine Clinical Diagnostics s.r.o, Thermo Fisher Scientific, PerkinElmer, GE Healthcare, Waters Corporation, Agilent Technologies, Bruker Corporation, Oxford Nanopore Technologies, 10x Genomics, Organovo Holdings, EMD Millipore, Cyprotex, RegeneMed Inc, HµREL Corporation, Nortis, In Silico Biosciences Inc, IOMICS Corporation, Charles River Laboratories, The Jackson Laboratory, Envigo, Taconic Biosciences, Inc., Cyagen Biosciences, Crown Biosciences, Harbour BioMed, Genewiz, Pacific Biosciences, Group 42 (G42) Healthcare, I-ONE, Wadi Jeddah Co, Philips, King Abdullah International Medical Research Center, Parexel, Soins Global, Pfizer South Africa, Dischem Pharmacy, Cipla Medpro South Africa Limited, Novartis South Africa, Synexa Life Sciences, IQVIA, Oceanic S. A, Hean

Get The Full Global Non Animal Alternatives Testing Market Report

Non Animal Alternatives Testing Market Overview

The non-animal alternatives testing is testing products and services that do not involve testing on animals to determine the safety and efficacy of products and ingredients used in any industry sector. Non-animal alternative testing technologies include: in-vitro human cell and tissue cultures; organs-on-chips (OOCs); computer simulations and modelling (silico models); 3D bio-printing of tissues; and synthetic skin substitutes; as well as studies with human volunteers. These technologies replace animal testing in end-use industries including pharmaceuticals, medical devices, chemicals and pesticides, food, and others.

Non Animal Alternatives Testing Global Market Report 2023 provides data on the global non animal alternatives testing market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The non animal alternatives testing market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.